Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell NewsKronos Bio, Inc. announced that the first patient has been dosed in a Phase Ib/II clinical trial of lanraplenib in combination with gilteritinib in patients with relapsed/refractory FLT3-mutated AML.
[Kronos Bio, Inc.]
Home Newsletters Hematopoiesis News Kronos Bio Announces First Patient Dosed in Phase 1b/2 Clinical Trial of...
